Pembrolizumab in Combination With Lenvatinib in Patients With Recurrent, Persistent, Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy

Conditions:   Recurrent Vulvar Cancer;   Persistent Vulvar Cancer;   Metastatic Vulva Cancer;   Locally Advanced Vulvar Cancer Interventions:   Drug: Pembrolizumab;   Drug: Lenvatinib Sponsor:   AGO Research GmbH Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials